Hypertonic saline during hospitalisation in Cystic Fibrosis study

Phase 3, placebo-controlled, parallel-group, randomised trial of the effect of nebulised hypertonic saline on the length of stay of people hospitalised with acute exacerbations of Cystic Fibrosis lung disease.

Status

Withdrawn

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000780651

Acronym

HSHS Trial

Enrollment

142

Registered

2005-12-07

Start date

2005-12-10

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

7% hypertonic saline with 0.25mg/mL quinine sulphate. The allocated trial solution is inhaled three times per day for the duration of a hospital admission.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

17 Years to No maximum

Healthy volunteers

Inclusion criteria

Cystic fibrosis

Exclusion criteria

B. cepacia, major haemoptysis in the last year, ITP, allergy to quinine sulphate, investigational drugs within last 30 days, previous lung transplant, pregnant or breastfeeding, thrombocytopaenia.

Outcome results